MedTrace Logo

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

NCT00711308 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2009-02-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility of the long-term treatment of pulmonary embolism with tinzaparin compared to oral anticoagulants.

Conditions

  • Acute Pulmonary Embolism

Interventions

DRUG

tinzaparin

tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months

DRUG

acenocoumarol

acenocoumarol for 6 months

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Complejo Hospitalario Xeral-Calde

    lead OTHER

Principal Investigators

  • Luis Pérez de Llano, MD · Complejo Hospitalario Xeral Calde (Lugo)

  • Alejandro Veres Racamonde, MD · Complejo Hospitalario Xeral Calde (Lugo)

  • Manuel Núnez Delgado, MD · Hospital do Meixoeiro (Vigo)

  • Ana Palacios Bartolomé, MD · Hospital Clínico de Santiago

  • Virginia Leiro Fernández, MD · Hospital Xeral (Vigo)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711308 on ClinicalTrials.gov